NICE hits milestone in UK's efforts to tackle antimicrobial resistance
The UK is set to become the first country to pay pharmaceutical companies a fixed fee for supplying antibiotics in an effort to tackle the growing global crisis over resistance to the drugs, according to a draft guidance published today by health technology assessor the National Institute of Health and Care Excellence (NICE).
In the NICE evaluations, Shionogi’s (TYO: 4507) Fetroja (cefiderocol) and Pfizer’s (NYSE: PFE) Zavicefta (ceftazidime–avibactam) form part of a project with NHS England and NHS Improvement and the Department of Health and Social Care (DHSC) that aims to incentivize research into and development of antimicrobials by testing new approaches to evaluating and paying for them.
The drugs will only be used to treat patients with severe drug-resistant infections who would otherwise have limited or no other treatment options.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze